FDA Lifts Partial Clinical Hold on Lorigerlimab for Gynecologic Cancer

FDA Lifts Partial Clinical Hold on Lorigerlimab for Gynecologic Cancer

The FDA has removed the partial clinical hold on the phase 2 LINNET study of lorigerlimab for patients with platinum-resistant ovarian cancer and clear cell gynecologic cancer.

FDA lifts MacroGenics hold; Oxford and Bristol Myers team up

Plus, news about Boston Oncology, Garda and Assertio, an Everest deal and Forte's raise: 🟢 FDA ends partial hold on MacroGenics cancer drug: In February, the agency stopped a Phase 2 trial of lorigerlimab after ...

Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb

Partnership to develop next‑generation T‑cell engagers for solid tumours